Biocon
India's largest biopharmaceutical company and global biosimilars leader
Why this company matters
Biocon is making expensive biologic drugs accessible to millions of patients worldwide through affordable biosimilars, reshaping global pharmaceutical economics.
- Key domain relevance: Biosimilars, Insulin, Oncology Biologics
- Active monitoring with 1 signals in the last 30 days across 3 tracked sources.
Channel Context
Biocon is a key company within the Healthtech & Biotech channel.Its official updates regularly contribute to how users track developments in this space, including strategic moves, partnerships, and technology shifts.
2 signals tracked to date in this channel.
View channelMarket Context
Biocon operates in a global market where SigFact tracks official signals from primary sources to provide timely, verified intelligence.
See recent signals in this marketStrategic themes and signal pattern
Strategic Themes
Recent Signal Pattern
Industry Peer Comparison
Key Changes (30d)
Biocon aims to serve 20% of the global insulin-dependent diabetic population within 10 years, leveraging its position as a top biosimilar player for rh-insulin and insulin glargine.
Biocon Aims to Serve One in Five Diabetic Patients Needing Insulin Globally
Signal history
2 totalThis is a commentary on a report about AI's potential impact on jobs, not a concrete new development.
Biocon obtains approval for weight management drug, Liraglutide, in the United States
Biocon has received approval from the U.S. Food and Drug Administration (FDA) for its Liraglutide injection, a drug used for weight management.
Biocon aims to serve 20% of the global insulin-dependent diabetic population within 10 years, leveraging its position as a top biosimilar player for rh-insulin and insulin glargine.
Biocon Aims to Serve One in Five Diabetic Patients Needing Insulin Globally
Biocon aims to provide its insulin products to one in five people with diabetes globally who require insulin-based therapy within the next 10 years. This ambitious goal builds on its existing success as a top global biosimilar player for rh-insulin and insulin glargine, having already made a difference to millions worldwide.
Peers and related companies
All companiesAstellas Pharma
Adv. marketMajor Japanese pharma company focused on urology, oncology, and transplantation
AstraZeneca
Anglo-Swedish pharma company with strong oncology and rare disease pipeline
BeiGene
Adv. marketChina's largest global biotech company focused on innovative oncology medicines
Biofourmis
Digital therapeutics and remote patient monitoring platform
CSL Limited
Global biotech leader in plasma-derived therapies and vaccines
Celltrion
Adv. marketSouth Korea's leading biosimilar manufacturer challenging global pharma giants
Continue monitoring Biocon
Follow this company, add it to your watchlist, or explore its signal stream to stay informed.